hmgcll1 Antibody

What is HMGCLL1 and what is its primary function in cellular metabolism?

HMGCLL1 (3-hydroxymethyl-3-methylglutaryl-CoA lyase-like protein 1) is a non-mitochondrial enzyme that catalyzes a cation-dependent cleavage of (S)-3-hydroxy-3-methylglutaryl-CoA into acetyl-CoA and acetoacetate. This reaction represents a key step in ketogenesis, with the resulting products supporting energy production in nonhepatic animal tissues. Unlike its mitochondrial counterpart HMGCL, HMGCLL1 is located extramitochondrially and exhibits distinct localization patterns dependent on post-translational modifications, particularly N-terminal myristoylation .

How does HMGCLL1 differ from mitochondrial HMGCL in terms of structure and function?

HMGCLL1 and mitochondrial HMGCL catalyze similar biochemical reactions but differ in cellular localization and structural features. Key differences include:

• Localization: HMGCLL1 is extramitochondrial, whereas HMGCL is mitochondrial

• Structural features: HMGCLL1 contains an N-terminal myristoylation motif absent in HMGCL

• Immunological distinction: Antibodies raised against unique N-terminal peptide sequences (residues 19-37) of HMGCLL1 can effectively discriminate between HMGCLL1 and mitochondrial HMGCL in immunodetection experiments

• Cellular distribution: While HMGCL shows typical mitochondrial distribution, wild-type HMGCLL1 exhibits punctate and perinuclear immunostaining patterns, indicating myristoylation-dependent association with non-mitochondrial membrane compartments

What post-translational modifications affect HMGCLL1 function and localization?

N-terminal myristoylation significantly affects HMGCLL1 cellular localization and potentially its function. Studies using site-directed mutagenesis have demonstrated:

• Wild-type HMGCLL1 undergoes myristoylation at the N-terminus, which can be confirmed through labeling experiments with [³H]myristoyl-CoA

• Mutation of the myristoylation site (G2A HMGCLL1) prevents this modification

• Wild-type (myristoylated) HMGCLL1 shows punctate and perinuclear immunostaining patterns, suggesting association with non-mitochondrial membrane compartments

• G2A HMGCLL1 mutant exhibits a diffuse pattern, consistent with cytosolic localization

This myristoylation-dependent membrane association likely influences HMGCLL1's accessibility to substrates and interaction partners, thereby modulating its metabolic functions.

What are the optimal expression systems for producing recombinant HMGCLL1 for antibody generation?

Expression of functional HMGCLL1 requires careful selection of expression systems. Based on experimental evidence:

• E. coli expression: Attempts to express HMGCLL1 in E. coli typically result in insoluble protein material, making this system suboptimal for functional protein production

• P. pastoris (yeast) expression: This eukaryotic expression system has been successfully used to produce active HMGCLL1 with appropriate post-translational modifications

• Mammalian expression: COS1 cells transfected with appropriate expression plasmids have been used to study subcellular localization and post-translational modifications of HMGCLL1

For antibody generation, researchers have successfully used fusion proteins of human HMGCLL1 as immunogens, with particular success targeting unique regions not conserved in mitochondrial HMGCL .

How can researchers validate the specificity of HMGCLL1 antibodies?

Validation of HMGCLL1 antibody specificity requires multiple complementary approaches:

• Western blot analysis:

  • Compare reactivity against recombinant HMGCLL1 versus HMGCL

  • Verify predicted molecular weight (approximately 40 kDa)

  • Test reactivity in known HMGCLL1-expressing tissues (e.g., human fetal liver)

• Immunohistochemistry validation:

  • Test antibody in multiple tissue types with known HMGCLL1 expression patterns

  • Include appropriate positive and negative controls

  • Compare staining patterns with subcellular markers to confirm expected localization

• Specificity testing:

  • Perform peptide competition assays using the immunizing peptide

  • Test cross-reactivity with related proteins, especially HMGCL

  • Evaluate antibody performance in knockout/knockdown models if available

• Application-specific validation:

  • For each experimental application (WB, IHC, ELISA), perform specific validation steps

  • Document optimal working dilutions for each application (e.g., 1:50-1:300 for IHC)

What are the key considerations when designing immunohistochemistry experiments using HMGCLL1 antibodies?

Successful immunohistochemistry experiments with HMGCLL1 antibodies require attention to several critical factors:

• Antibody selection: Choose antibodies validated for IHC applications with demonstrated specificity for HMGCLL1 over HMGCL

• Tissue preparation and fixation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues have been successfully used with several HMGCLL1 antibodies

  • Consider antigen retrieval methods to ensure optimal epitope exposure

• Dilution optimization:

  • Typical working dilutions range from 1:50-1:300 based on commercial antibody specifications

  • Always perform a dilution series to determine optimal antibody concentration for each tissue type

• Controls:

  • Include positive control tissues (e.g., human fetal brain, liver cancer, or colorectal cancer tissues)

  • Include negative controls (omission of primary antibody)

  • Consider including tissues with known HMGCL but not HMGCLL1 expression to confirm specificity

• Staining pattern interpretation:

  • Wild-type HMGCLL1 typically shows punctate and perinuclear staining

  • Compare with known subcellular markers to confirm extramitochondrial localization

How does HMGCLL1 genetic variation correlate with treatment response in chronic myeloid leukemia?

HMGCLL1 genetic variants have emerged as potential biomarkers for predicting treatment response in chronic myeloid leukemia (CML). Research findings indicate:

• A specific HMGCLL1 genetic variant located in chromosome 6p12.1 functions as a predictive genetic biomarker for intrinsic sensitivity to imatinib (IM) therapy

• This correlation has been validated in multiple patient cohorts:

  • Discovery set (n=201 CML patients)

  • Validation set (n=270 CML patients)

• The HMGCLL1 variant predicts deep molecular response (DMR) to tyrosine kinase inhibitor (TKI) therapy

• Functional studies support this association, as siRNA-mediated blockade of HMGCLL1 isoform 3 results in significant decreases in viability of BCR-ABL1-positive cell lines (K562, CML-T1, BaF3), including those with ABL1 kinase domain mutations like T315I

• The mechanism appears to involve cell cycle regulation, with HMGCLL1 blockade associated with G0/G1 arrest

These findings suggest HMGCLL1 may represent both a predictive biomarker and potential therapeutic target in CML.

What experimental approaches can be used to study HMGCLL1's role in metabolic diseases?

Given HMGCLL1's role in ketogenesis and potential association with metabolic conditions such as non-alcoholic fatty liver disease (NAFLD) , several experimental approaches can elucidate its function:

• Genetic association studies:

  • Analyze HMGCLL1 polymorphisms in patient cohorts with metabolic disorders

  • Correlate genetic variants with disease phenotypes and treatment responses

• Expression analysis:

  • Compare HMGCLL1 expression levels in normal versus diseased tissues using:

    • qRT-PCR for mRNA quantification

    • Western blot analysis with validated antibodies for protein expression

    • Immunohistochemistry to assess tissue and cellular distribution patterns

• Functional studies:

  • siRNA or CRISPR-based knockdown/knockout models in relevant cell lines

  • Metabolic flux analysis to measure effects on ketogenesis and related pathways

  • Cell-based assays to assess viability, proliferation, and metabolic parameters

• Animal models:

  • Generate tissue-specific or inducible HMGCLL1 knockout mice

  • Expose models to metabolic challenges (high-fat diet, fasting) and measure:

    • Ketone body production

    • Lipid accumulation in liver

    • Glucose tolerance and insulin sensitivity

• Biochemical characterization:

  • Enzyme activity assays measuring conversion of HMG-CoA to acetoacetate and acetyl-CoA

  • Substrate specificity and kinetic parameter comparison with HMGCL

How might HMGCLL1 interact with other metabolic enzymes in cellular energy homeostasis?

HMGCLL1's extramitochondrial localization suggests it may participate in distinct metabolic networks compared to mitochondrial HMGCL. Potential interaction networks and research approaches include:

• Protein-protein interaction studies:

  • Co-immunoprecipitation using HMGCLL1 antibodies to identify binding partners

  • Proximity labeling approaches (BioID, APEX) to identify proteins in close proximity

  • Yeast two-hybrid screening or protein array analyses

• Metabolic pathway integration:

  • Investigate HMGCLL1's relationship with cytosolic/ER-associated metabolic enzymes

  • Examine potential links to:

    • Cholesterol synthesis pathway enzymes

    • Fatty acid metabolism

    • Cytosolic acetyl-CoA utilizing pathways

• Subcellular compartmentalization analysis:

  • Co-localization studies with organelle markers using immunofluorescence

  • Subcellular fractionation followed by Western blot analysis

  • Live-cell imaging with fluorescently tagged HMGCLL1

• Systems biology approaches:

  • Metabolomics analysis in HMGCLL1-modulated systems

  • Transcriptomics to identify co-regulated genes

  • Network analysis to position HMGCLL1 within broader metabolic pathways

What strategies can resolve contradictory data when using different HMGCLL1 antibodies?

When facing contradictory results with different HMGCLL1 antibodies, employ these systematic troubleshooting approaches:

• Epitope mapping and antibody characterization:

  • Determine the precise epitopes recognized by each antibody

  • Compare antibodies targeting different regions of HMGCLL1 (N-terminal, internal, C-terminal)

  • Assess whether different isoforms or post-translationally modified forms may be differentially detected

• Validation with genetic controls:

  • Implement siRNA knockdown or CRISPR knockout of HMGCLL1

  • Test antibodies against these negative controls to confirm specificity

  • Use overexpression systems with tagged HMGCLL1 as positive controls

• Cross-platform validation:

  • Compare results across multiple techniques (WB, IHC, IF, ELISA)

  • Employ orthogonal detection methods that don't rely on antibodies (e.g., mass spectrometry)

  • Use mRNA detection techniques to corroborate protein expression patterns

• Detailed protocol comparison:

  • Standardize protocols across experiments

  • Systematically vary fixation methods, antigen retrieval techniques, and blocking conditions

  • Document the effect of each variable on antibody performance

• Technical replicate analysis:

  • Perform multiple independent experiments

  • Quantify variability between replicates

  • Apply appropriate statistical analyses to determine significance of observed differences

How can researchers effectively discriminate between HMGCLL1 and HMGCL in complex biological samples?

Distinguishing between the extramitochondrial HMGCLL1 and mitochondrial HMGCL requires careful experimental design:

• Antibody-based discrimination:

  • Use antibodies raised against unique N-terminal sequences of HMGCLL1 (e.g., residues 19-37) that aren't conserved in HMGCL

  • Validate antibody specificity using recombinant HMGCLL1 and HMGCL proteins

  • Perform peptide competition assays to confirm epitope specificity

• Subcellular fractionation approaches:

  • Separate mitochondrial fractions from cytosolic/membrane fractions

  • Perform Western blot analysis on separated fractions

  • Include markers for mitochondria (e.g., cytochrome c) and other compartments as controls

• Immunofluorescence co-localization:

  • Co-stain samples with HMGCLL1 antibodies and mitochondrial markers

  • Use confocal microscopy to assess co-localization

  • Quantify spatial relationships using appropriate co-localization statistics

• Functional discrimination:

  • Design assays that exploit differences in post-translational modifications

  • Utilize inhibitors or conditions that differentially affect each enzyme

  • Measure enzyme activity in purified subcellular fractions

What advanced imaging techniques are most informative for studying HMGCLL1 subcellular localization?

Given HMGCLL1's complex subcellular distribution patterns influenced by myristoylation, several advanced imaging approaches provide valuable insights:

• Super-resolution microscopy techniques:

  • Structured illumination microscopy (SIM) to resolve punctate HMGCLL1 structures beyond the diffraction limit

  • Stochastic optical reconstruction microscopy (STORM) or photoactivated localization microscopy (PALM) for nanoscale resolution

  • Stimulated emission depletion (STED) microscopy for detailed membrane association studies

• Live-cell imaging approaches:

  • HMGCLL1-fluorescent protein fusions (both wild-type and G2A mutants)

  • Photoactivatable or photoconvertible tags to track protein dynamics

  • FRAP (fluorescence recovery after photobleaching) to measure protein mobility

• Multi-color co-localization studies:

  • Triple labeling with HMGCLL1, mitochondrial markers, and markers for:

    • Endoplasmic reticulum

    • Golgi apparatus

    • Lipid droplets

    • Peroxisomes

  • Quantitative co-localization analysis with appropriate statistical measures

• Correlative light and electron microscopy (CLEM):

  • Combine fluorescence microscopy of HMGCLL1 with ultrastructural context

  • Immunogold labeling for transmission electron microscopy

  • Focused ion beam-scanning electron microscopy (FIB-SEM) for 3D ultrastructural context

How does the myristoylation status of HMGCLL1 affect antibody recognition and experimental outcomes?

The N-terminal myristoylation of HMGCLL1 can significantly impact antibody binding and experimental results:

• Epitope accessibility concerns:

  • Antibodies targeting the N-terminal region may have differential access to myristoylated versus non-myristoylated forms

  • Membrane association of myristoylated HMGCLL1 may mask certain epitopes

  • Consider using multiple antibodies targeting different regions of the protein

• Experimental considerations:

  • For immunoprecipitation: Detergent selection is critical; insufficient solubilization may result in underrepresentation of membrane-associated myristoylated forms

  • For Western blot: Inclusion of appropriate controls (recombinant myristoylated and non-myristoylated forms)

  • For IHC/IF: Fixation methods may differentially preserve myristoylated versus non-myristoylated forms

• Analytical approaches:

  • Express both wild-type and G2A mutant HMGCLL1 as controls

  • Use myristoylation-specific detection methods (e.g., click chemistry with azido-myristate)

  • Compare antibody recognition patterns between wild-type and G2A mutants

• Data interpretation guidelines:

  • Document subcellular distribution patterns in detail

  • Consider the possibility of mixed populations of myristoylated and non-myristoylated HMGCLL1

  • Interpret quantitative results in the context of potential myristoylation-dependent differences in extraction or detection efficiency

What experimental approaches would best elucidate the mechanistic link between HMGCLL1 variants and treatment response in leukemia?

To further investigate how HMGCLL1 variants influence treatment response in leukemia, consider these methodological approaches:

• Detailed genetic and molecular characterization:

  • Fine-mapping of the 6p12.1 locus to identify causative variants

  • Epigenetic profiling to assess potential regulatory mechanisms

  • Transcript analysis to determine if variants affect splicing or expression levels of specific HMGCLL1 isoforms

• Functional genomics approaches:

  • CRISPR-based genome editing to introduce or correct specific variants

  • Isogenic cell line pairs differing only in HMGCLL1 variant status

  • Patient-derived xenograft models comparing treatment responses based on HMGCLL1 genotype

• Mechanistic studies linking HMGCLL1 to drug response:

  • Metabolomic profiling before and after TKI treatment in cells with different HMGCLL1 variants

  • Phosphoproteomic analysis to identify signaling differences

  • Analysis of cell cycle parameters and apoptotic responses to TKIs

• Clinical translation studies:

  • Prospective clinical trials stratifying patients by HMGCLL1 genotype

  • Development of companion diagnostics

  • Testing combination therapies targeting both BCR-ABL1 and HMGCLL1-regulated pathways

How can researchers integrate multi-omics data to better understand HMGCLL1's role in cellular metabolism?

A comprehensive multi-omics approach to understand HMGCLL1 function would include:

• Integrated genomics, transcriptomics, and proteomics:

  • Genome-wide association studies linking HMGCLL1 variants to metabolic phenotypes

  • RNA-seq analysis to identify co-regulated gene networks

  • Proteomics to identify interaction partners and post-translational modifications

  • Integration of these datasets using systems biology approaches

• Metabolomics and fluxomics approaches:

  • Steady-state metabolomics in HMGCLL1-modulated systems

  • 13C-metabolic flux analysis to trace carbon flow through HMGCLL1-dependent pathways

  • Comparison of extramitochondrial versus mitochondrial ketogenic pathways

• Spatial multi-omics integration:

  • Single-cell transcriptomics combined with spatial transcriptomics

  • Subcellular proteomics comparing different cellular compartments

  • Correlating HMGCLL1 localization with local metabolite concentrations

• Computational modeling and network analysis:

  • Constraint-based metabolic modeling incorporating HMGCLL1 activity

  • Bayesian network analysis to infer causal relationships

  • Machine learning approaches to identify patterns across multi-omics datasets

What techniques would best characterize the enzyme kinetics of HMGCLL1 compared to HMGCL?

Comprehensive enzyme kinetic characterization requires:

• Protein expression and purification optimization:

  • Expression in P. pastoris or mammalian systems to ensure proper folding and modifications

  • Establish purification protocols that preserve HMGCLL1 activity

  • Produce both wild-type and G2A mutant forms to assess myristoylation effects on kinetics

• Steady-state kinetic measurements:

  • Determine Km, kcat, and kcat/Km for HMG-CoA

  • Assess cation requirements and optimal pH/temperature

  • Compare directly with HMGCL under identical conditions

• Advanced kinetic analyses:

  • Pre-steady-state kinetics using stopped-flow techniques

  • Isothermal titration calorimetry to measure binding thermodynamics

  • Substrate specificity profiling with substrate analogs

• Structure-function relationship studies:

  • Site-directed mutagenesis of conserved and divergent residues

  • Circular dichroism and thermal shift assays to assess structural stability

  • Crystallography or cryo-EM structural determination if possible

• Membrane/lipid influence assessment:

  • Compare activity in solution versus membrane-associated contexts

  • Test effects of different lipid compositions on enzyme activity

  • Develop assays that account for the potential membrane association of myristoylated HMGCLL1